Pressmeddelanden, rapporter och bolagsmeddelande för ChemoMetec

ChemoMetec A/S has received a notification under Article 19 of EU Regulation no. 596/2014 regarding share transactions made by people holding managerial responsibilities in the company, or those closely associated with them. The transactions of CEO Martin Helbo Behrens can be found in the attached PDF document. ChemoMetec A/S is a company that develops, manufactures, and markets instruments for cell counting and other measurements, catering to pharmaceutical, biotech, and agricultural industries worldwide.

ChemoMetec's Q3 2023/24 revenue fell by 6% to DKK 98.9 million, reflecting growth in sales of consumables and services but declining sales of instruments. EBITDA also fell to DKK 43.1 million due to higher staff costs and organisational changes. The company's new products, the XcytoMatic 40 (XM40) and XcytoMatic 30 (XM30), attracted customer interest, with the first sale of the XM30 completed. Sales of XM40 reached DKK 2 million. ChemoMetec plans to introduce a new software platform in the coming months and continue selling the XM40 in the bioprocessing market. The company's future growth depends on becoming the preferred cell counting partner in the pharmaceutical/biotech industry, driven by an increasing demand for automation. The XM30 project had reached the late prototype stage by the end of Q3. Despite a revenue decline, sales of consumables and services continue to rise. ChemoMetec's largest geographical market remains the USA/Canada region. EBITDA for the first nine months of 2023/24 fell 32% to DKK 136.2 million. The company clarified its full-year 2023/24 revenue guidance to the DKK 400-415 million range and lowered its EBITDA guidance to the DKK 185-200 million range.

The preliminary figures for ChemoMetec's third quarter of the 2023/24 financial year show revenue of DKK 98.9 million, and DKK 298.2 million for the first nine months. Based on these figures and future expectations, ChemoMetec has revised its revenue forecast for the 2023/24 financial year to be in the DKK 400-415 million range, down from the previous DKK 400-435 million. Earnings in the third quarter have been impacted by one-time costs due to organizational changes, leading to an expected operating result (EBITDA) of DKK 185-200 million, down from the previously announced DKK 200-220 million. The final figures for the third quarter and the first nine months of 2023/24 will be included in the interim report for the third quarter, to be published on 8 May 2024.

BlackRock, Inc. has increased its holding of voting rights in ChemoMetec A/S to more than 10%, exceeding the limit set by section 38 of the Capital Markets Act. The total share capital and voting rights of BlackRock, Inc. in ChemoMetec A/S now stands at 13.48%. ChemoMetec A/S, a company that develops, manufactures and markets instruments for cell counting and other measurements, is listed on Nasdaq OMX Copenhagen.

Swedbank Robur Fonder AB has announced a reduction in its share and voting rights in ChemoMetec A/S, to below 5% as of 2 April 2024. This information was disclosed in compliance with Section 38 of the Danish Capital Markets Act. ChemoMetec A/S, a company that manufactures and sells cell counting instruments, is listed on Nasdaq OMX Copenhagen and serves several leading pharmaceutical companies worldwide.